PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17992263-6	2007	Exogenous rIL-1beta recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation.	Bleomycin	166-175	interleukin 1 receptor, type I	Mus musculus	110-116	
17992263-8	2007	In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.	Bleomycin	15-24	interleukin 1 receptor, type I	Mus musculus	78-84	
27306439-15	2016	This study demonstrated that FD, attenuates BLM-induced pulmonary inflammation and fibrosis in mice via inhibiting the activation of NALP3 inflammasome and the IL-1beta/IL-1R1/MyD88/ NF-kappaB pathway.	Bleomycin	44-47	interleukin 1 receptor, type I	Mus musculus	169-175	
24172847-6	2014	Finally, Il1r1-/- and Il1a-/- mice exhibit reduced bronchoalveolar lavage (BAL) neutrophilia and collagen deposition in response to bleomycin treatment.	Bleomycin	132-141	interleukin 1 receptor, type I	Mus musculus	9-14